Cancer Therapies

Phase I Testing for a Ras Pathway Inhibitor Initiated

Published in Gene Therapy Weekly, August 3rd, 2000

Onyx Pharmaceuticals, Inc. announced that the company, along with its partner Bayer Corporation, initiated Phase I clinical testing in Germany for a Ras pathway inhibitor as a cancer therapy.

A U.S. Investigational New Drug Application (IND) for this compound was filed in May 2000. Additional international regulatory filings for Phase I multi-dose trials in Canada and Belgium are planned.

A key function of the Ras pathway is cell proliferation. In normal cell proliferation, when the Ras pathway is activated, or "on," it sends a signal telling the cell to grow and divide. When a gene in the pathway is mutated, the signal may not turn "off," causing...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-08-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry